Zollinger-Ellison syndrome classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 9: | Line 9: | ||
*Considering their origin, gastrinomas are generally classified under the larger entity such as the [[neuroendocrine tumors]] (NETs). | *Considering their origin, gastrinomas are generally classified under the larger entity such as the [[neuroendocrine tumors]] (NETs). | ||
*Among the [[enteroendocrine cells]] that arise from the [[embryologic]] [[endoderm]], the gastrinomas are derived mainly from the [[pancreas]], and also from the proximal [[small intestine]]. <ref name="pmid7904550">{{cite journal |vauthors=Norton JA |title=Neuroendocrine tumors of the pancreas and duodenum |journal=Curr Probl Surg |volume=31 |issue=2 |pages=77–156 |year=1994 |pmid=7904550 |doi= |url=}}</ref> | *Among the [[enteroendocrine cells]] that arise from the [[embryologic]] [[endoderm]], the gastrinomas are derived mainly from the [[pancreas]], and also from the proximal [[small intestine]]. <ref name="pmid7904550">{{cite journal |vauthors=Norton JA |title=Neuroendocrine tumors of the pancreas and duodenum |journal=Curr Probl Surg |volume=31 |issue=2 |pages=77–156 |year=1994 |pmid=7904550 |doi= |url=}}</ref> | ||
*According to the [[World Health Organization]], [[neuroendocrine tumors]] (NETs) are classified into two broad categories; well differentiated, and poorly differentiated gastrinomas. On the basis of [[histopathological]] analysis, most of the [[Gastrinoma|gastrinomas]] are considered well-differentiated [[neuroendocrine tumors]] (NETs) | *According to the [[World Health Organization]], [[neuroendocrine tumors]] (NETs) are classified into two broad categories; well differentiated, and poorly differentiated gastrinomas. On the basis of [[histopathological]] analysis, most of the [[Gastrinoma|gastrinomas]] are considered well-differentiated [[neuroendocrine tumors]] (NETs). <ref name="pmid23582915">{{cite journal| author=O'Toole D, Delle Fave G, Jensen RT| title=Gastric and duodenal neuroendocrine tumours. | journal=Best Pract Res Clin Gastroenterol | year= 2012 | volume= 26 | issue= 6 | pages= 719-35 | pmid=23582915 | doi=10.1016/j.bpg.2013.01.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23582915 }} </ref> | ||
* | |||
*The WHO (2010) classified all neuroendocrine tumors, including [[Gastrinoma|gastrinomas]] into three grades based on the mitotic rate, or Ki-67 index: <ref name="pmid28722872">{{cite journal |vauthors=Cingam S, Karanchi H |title= |journal= |volume= |issue= |pages= |year= |pmid=28722872 |doi= |url=}}</ref> | *The WHO (2010) classified all neuroendocrine tumors, including [[Gastrinoma|gastrinomas]] into three grades based on the mitotic rate, or Ki-67 index: <ref name="pmid28722872">{{cite journal |vauthors=Cingam S, Karanchi H |title= |journal= |volume= |issue= |pages= |year= |pmid=28722872 |doi= |url=}}</ref> | ||
: | :{| class="wikitable" | ||
!Grade | |||
!Diffrentiation | |||
!Mitotic range | |||
!Ki-67 index | |||
!Behavior | |||
|- | |||
|G1 | |||
|Low grade well-differentiated | |||
|< 2 | |||
|< 3% (10% to 30%) | |||
|Uncertain | |||
|- | |||
|G2 | |||
|Intermediate grade, well-differentiated | |||
|2 to 20 | |||
|3% to 20% (50% to 80%) | |||
|Low-grade malignant | |||
|- | |||
|G3 | |||
|High grade, poorly differentiated | |||
|> 20 | |||
|> 20% (1% to 3%) | |||
|High-grade malignant | |||
|} | |||
*The following table illustrates the factors associated and the differences between Sporadic and MEN-1-associated ZES: <ref name="pmid24319020">{{cite journal |vauthors=Epelboym I, Mazeh H |title=Zollinger-Ellison syndrome: classical considerations and current controversies |journal=Oncologist |volume=19 |issue=1 |pages=44–50 |year=2014 |pmid=24319020 |pmc=3903066 |doi=10.1634/theoncologist.2013-0369 |url=}}</ref> | *The following table illustrates the factors associated and the differences between Sporadic and MEN-1-associated ZES: <ref name="pmid24319020">{{cite journal |vauthors=Epelboym I, Mazeh H |title=Zollinger-Ellison syndrome: classical considerations and current controversies |journal=Oncologist |volume=19 |issue=1 |pages=44–50 |year=2014 |pmid=24319020 |pmc=3903066 |doi=10.1634/theoncologist.2013-0369 |url=}}</ref> | ||
Revision as of 18:42, 6 September 2017
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome classification On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome classification |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
- According to the World Health Organization, neuroendocrine tumors (NETs) are classified into two broad categories namely, well differentiated and poorly differentiated. On the basis of histopathological analysis, most gastrinomas are considered well-differentiated neuroendocrine tumors (NETs).
Classiffication
- Considering their origin, gastrinomas are generally classified under the larger entity such as the neuroendocrine tumors (NETs).
- Among the enteroendocrine cells that arise from the embryologic endoderm, the gastrinomas are derived mainly from the pancreas, and also from the proximal small intestine. [1]
- According to the World Health Organization, neuroendocrine tumors (NETs) are classified into two broad categories; well differentiated, and poorly differentiated gastrinomas. On the basis of histopathological analysis, most of the gastrinomas are considered well-differentiated neuroendocrine tumors (NETs). [2]
- The WHO (2010) classified all neuroendocrine tumors, including gastrinomas into three grades based on the mitotic rate, or Ki-67 index: [3]
Grade Diffrentiation Mitotic range Ki-67 index Behavior G1 Low grade well-differentiated < 2 < 3% (10% to 30%) Uncertain G2 Intermediate grade, well-differentiated 2 to 20 3% to 20% (50% to 80%) Low-grade malignant G3 High grade, poorly differentiated > 20 > 20% (1% to 3%) High-grade malignant
- The following table illustrates the factors associated and the differences between Sporadic and MEN-1-associated ZES: [4]
| Sporadic and MEN-1-associated ZES | ||
| Factors | Sopradic ZES | MEN-1 ZES |
|---|---|---|
|
|
|
References
- ↑ Norton JA (1994). "Neuroendocrine tumors of the pancreas and duodenum". Curr Probl Surg. 31 (2): 77–156. PMID 7904550.
- ↑ O'Toole D, Delle Fave G, Jensen RT (2012). "Gastric and duodenal neuroendocrine tumours". Best Pract Res Clin Gastroenterol. 26 (6): 719–35. doi:10.1016/j.bpg.2013.01.002. PMID 23582915.
- ↑ Cingam S, Karanchi H. PMID 28722872. Missing or empty
|title=(help) - ↑ Epelboym I, Mazeh H (2014). "Zollinger-Ellison syndrome: classical considerations and current controversies". Oncologist. 19 (1): 44–50. doi:10.1634/theoncologist.2013-0369. PMC 3903066. PMID 24319020.